Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Rivaroxaban for Thromboprophylaxis After Nonelective Orthopedic Trauma Surgery in Switzerland

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Trilogy-constrained Acetabular Component for Recurrent Dislocation

    Research output: Contribution to journalJournal articleCommunication

  2. Cement oscillation increases interlock strength at the cement-bone interface: Commentary

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Segmental blood pressure after total hip replacement.

    Research output: Contribution to journalJournal articleResearch

  4. Osteoarthritis after Colles' fracture

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Lectin pathway proteins of the complement system in normotensive pregnancy and pre-eclampsia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of HIT Antibody Complex in Hip Fracture Patients Receiving Enoxaparin or Unfractionated Heparin

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Pierre Hoffmeyer
  • Hanspeter Simmen
  • Marcel Jakob
  • Christoph Sommer
  • Andreas Platz
  • Thomas Ilchmann
  • Erik Grossen
  • Christian Ryf
  • Panayiotis Christofilopoulos
  • Michael Schueler
  • Michael Rud Lassen
  • Markus Rimle
  • Urs E Gasser
View graph of relations

This study investigated the effectiveness and the outcomes of rivaroxaban vs the standard of care for venous thromboembolic prophylaxis in patients undergoing fracture-related surgery. A total of 413 patients undergoing fracture-related surgery from 9 Swiss orthopedic and trauma centers were enrolled. The authors selected the type of venous thromboembolic prophylaxis according to standardized medical practice at the participating centers before the inclusion of patients: 208 patients received rivaroxaban and 205 received the standard of care. Data on symptomatic thromboembolic and bleeding events, surgery-related complications, death, adverse events, time to mobilization, and hospital discharge were collected. Symptomatic thromboembolic events were reported in 1 patient (0.5%) and 2 patients (1.0%) and treatment-emergent major bleeding events were reported in 1 patient (0.5%) and 2 patients (1.0%) receiving rivaroxaban and the standard of care, respectively. The durations of hospital stay and venous thromboembolic prophylaxis were similar in the 2 groups. In both groups, adverse events related to venous thromboembolic prophylaxis were reported in 12 patients. The proportion of patients with minor and major fracture surgery was 74.3% and 25.7%, respectively. In patients undergoing minor fracture surgery receiving rivaroxaban (n=167) and the standard of care (n=140), no symptomatic thromboembolic events and no major bleeding events were reported. Outcomes of this study indicate that rivaroxaban might be an appropriate oral alternative for venous thromboembolic prophylaxis in routine medical care after fracture-related major and minor surgery. Reported results were comparable to those from other large-scale, noninterventional and randomized controlled studies. [Orthopedics. 201x; xx(x):xx-xx.].

Original languageEnglish
JournalOrthopedics
Volume40
Issue number2
Pages (from-to)109-116
ISSN0147-7447
DOIs
Publication statusPublished - 2017

ID: 49687587